Determining Metabolic Effects of Valproate and Antipsychotic Therapy
Metabolic Effects of Valproate and Antipsychotic Therapy
Sponsor: National Institute of Mental Health (NIMH)
This NA trial investigates Schizophrenia and is currently completed. National Institute of Mental Health (NIMH) leads this study, which shows 10 recorded versions since 2004 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed NA
-
Mar 2020 — Jan 2021 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jun 2018 — Mar 2020 [monthly]
Unknown Status NA
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status NA
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status NA
First recorded
Dec 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Mental Health (NIMH)
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .